Viramidine (Ribapharm).
Viramidine, an analog of ribavirin is a broad-spectrum antiviral under development by Ribapharm (previously the R&D division of ICN Pharmaceuticals) for the potential treatment of viral infections [378507]. In September 2000, phase I trials began in Europe. In December 2001, the company filed a US IND for the clinical development of viramidine as part of a combination therapy with interferon-afor the treatment of chronic hepatitis C virus (HCV) infection [435007], [441613]; a phase I trial was initiated in the US in late March 2002 [435598]. In November 2002, Ribapharm reported that it would start phase II trials of viramidine in the treatment of chronic HCV by the end of 2002 [469062].
Barnard
Dale
D
Institute for Antiviral Research, Utah State University, 5600 Old Main Hill Logan, UT 84322-5600, USA. honery@cc.usu.edu
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D012254:Ribavirin / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
D012254:Ribavirin; C026956:taribavirin